EGFR and non-small cell lung carcinoma: Previously, it has been reported that patients with epidermal growth factor receptor (EGFR) mutation‐positive NSCLC can develop a disease flare upon discontinuation of EGFR‐TKI therapy,13 indicating that EGFR mutation‐positive tumors continue to depend on EGFR signaling.